Daily Dose - May 16th, 2024
 
 
Daily Dose | View online
 
May 16, 2024
Data-driven decision-making and analytics capabilities can be the difference between success and failure in pharmaceutical operations. But many companies are missing opportunities to leverage available data.
The drug failed improve clinical outcomes related to function, breathing or strength in a phase 1/2 trial.
J&J will pay up to $850 million and pick up two promising bispecific antibodies.
Sponsored
Dive into the nuances of data integrity as experts from Blue Mountain and Barry-Wehmiller Design Group discuss the challenges organizations face and how they overcome them